Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / AVEO Pharmaceuticals, Inc.

Clinicaltrial registered22 Oct 2026

AVEO Pharmaceuticals, Inc.

22 Oct 2026: Trial registered · Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
22 Oct 2026
Title
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
Conditions
Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
Phase
Phase 2, Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07888075
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at AVEO Pharmaceuticals, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.